New Recruiting Trial: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
WHY IT MATTERS
This Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.
NCT ID: NCT07422480 Title: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions Status: RECRUITING Phase: PHASE3 Sponsor: Takeda Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07422480 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have MDS and receive regular blood transfusions, ask your doctor if you meet the eligibility criteria for this trial at NCT07422480, which is now recruiting patients.